The new way to build the bioeconomy.
Collaborative cyber-physical AI agents for the innovators who design and make advanced formulations and devices serving human health and the environment.
PARTNERED WITH INNOVATORS AT
The bioeconomy is at a turning point.
Manufacturing, materials and biology are accelerating in parallel, while AI can deliver a new paradigm of operational efficiency through intelligent automation.
What hasn't kept pace is the computational and robotic infrastructure to conceive, design, validate, launch, and manufacture these products. Every innovator at every scale runs the same loop in manual, trial & error mode: the DMTA loop.
DMTA Breaks at Every Transition.
"Design happens in one system, Make in another, Test in a third, Analyze in a fourth. Data does not flow across stages. Knowledge does not compound across experiments. The integrative orchestration layer that would close the loop does not yet exist."
Each DMTA stage lives in a different silo
Design happens in one system, Make in another, Test in a third, Analyze in a fourth: ELN/LIMS, CAD/CAM, MES, ERP, QMS, CRM. Each excellent on its own, none of them talking to the next.
Spreadsheets are the connective tissue
Despite the existence of enterprise stacks, the handoffs between tools happen through Excel exports, PDF reports, and late spreadsheets, used as infrastructure rather than analysis.
Institutional knowledge lives in someone's head
What works, what failed, and what to try next is held by one or two senior engineers. When they're out, the loop stalls. Experiments don't accumulate. They're rerun.
Loominus Designs & Orchestrates. BioLoom Prints. MetaLab Formulates.
With the BLI Tech Stack, you can create cyber-physical agents that automate the DMTA loop — design, make, test, analyze — the cycle every product innovation depends on.
Where our systems operate today
A 5-level scale for self-driving labs, from assisted operation to full autonomy.
Operates at L2–L3 depending on workflow configuration.
Launches at L3 — full DMTA cycles with human review of anomalies. Architected for a path to L4.
One closed loop. Every industry you operate in. Always learning.
Our platform democratizes the same 3 primitives that are going to drive the next wave of product innovation in every physical bioeconomy sector: → Agents → Connected Hardware → Shared Intelligence that improves over time.
Built for Every Team in the Bioeconomy.
Industry-agnostic across the bioeconomy, with deep traction in life sciences, pharma, and consumer & industrial bio-innovation.
Industrial Superintelligence. Measurable ROI.
Imagine your product innovation pipeline powered by your entire knowledge base operating with full traceability, unlocking new product form factors and supply chains and dramatically accelerating time-to-market.
One Environment. Every Role That Ships an Agentic Workflow.
Scientists, engineers, operators, leaders, and IT all collaborate inside Loominus. The platform meets each group where they are — from authoring a first workflow to running it in production and governing it across the program.
Builders
Scientists, R&D engineers, IT
Author agentic workflows, compose graphs of Skills, and integrate instruments, backends, and data sources. Iterate in simulation and replay before a single reagent is consumed in the lab.
Operators
Process engineers, manufacturing leads, lab managers, QA
Run autonomous workflows in production, monitor live executions across instruments and sites, approve human-in-the-loop checkpoints, and intervene the moment a run needs hands-on attention.
Leaders & Stewards
R&D and manufacturing directors, regulatory, IP & innovation
Govern programs end-to-end with capability-scoped permissions and full audit trails. See ROI across the pipeline and turn experiment exhaust into compounding, defensible knowledge.
Continue Exploring.
Stay ahead of the curve
Updates on the BLI Tech Stack, system design, and applied research.
Topics of interest
No spam. Unsubscribe anytime. We respect your inbox.
See the System in Action.
Discover how BLI empowers your team to discover, design, and fabricate biomaterial products at speeds and scales far beyond traditional methods.